Last reviewed 2026-04-23 · How we verify

Epo-alpha

Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients with HIV infection.

At a glance

Mechanism of action

Epo-alpha mimics the natural hormone erythropoietin, which regulates red blood cell formation in response to tissue hypoxia. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation, differentiation, and maturation of these cells into functional red blood cells. This mechanism is used therapeutically to treat anemia by increasing hemoglobin and hematocrit levels.

Approved indications

• Anemia associated with chronic kidney disease
• Anemia in cancer patients receiving chemotherapy
• Anemia in patients with HIV infection

Common side effects

• Hypertension
• Headache
• Thrombotic events (DVT, PE, stroke)
• Injection site reactions
• Flu-like symptoms
• Pure red cell aplasia

Key clinical trials

• High Dose of Erythropoietin Analogue After Cardiac Arrest (PHASE3)
• Long Term Beta Thalassemia Treatment: Findings From The Extension Period (PHASE2)
• Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
• Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child (NA)
• A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE2)
• A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (PHASE3)
• The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (PHASE2)
• Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.